Full-length serine protein kinase in brain and pancreas

Abstract

The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science, pathology, and medicine, etc. The polynucleotides are expressed in brain and pancreas and are therefore useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions, especially relating to brain and pancreas.

1 . An isolated polynucleotide KSE336 which codes without interruption for an amino acid sequence set forth in SEQ ID NO 2 or SEQ ID NO 4, or a complement thereto.  
     
     
         2 . An isolated polynucleotide KSE336 which has 99% or more sequence identity to a polynucleotide set forth in SEQ ID NO. 1 or 3, or a complement thereto.  
     
     
         3 . An isolated polynucleotide of  claim 1 , which is SEQ ID NO 1.  
     
     
         4 . An isolated polynucleotide of  claim 3 , which is SEQ ID NO 3.  
     
     
         5 . An isolated polynucleotide of  claim 1 , which has SEQ ID NO 1 or SEQ IS NO 3, except for a polymorphism of Table 1.  
     
     
         6 . An isolated polynucleotide consisting of: 
 a polynucleotide fragment coding for an amino acid sequence of SEQ ID NO. 6, a fragment thereof which is specific for KSE336-1, or a complement thereto.    
     
     
         7 . An isolated polypeptide coded for by a polynucleotide of  claim 1 .  
     
     
         8 . A method of treating a disease of brain or pancreas showing altered expression of KSE336, comprising: 
 administering to a subject in need thereof a therapeutic agent which is effective for regulating expression of said KSE336 of  claim 1 .    
     
     
         9 . A method of  claim 8 , wherein said agent is an antibody or an antisense which is effective to inhibit translation of said gene.  
     
     
         10 . A method of diagnosing a brain or pancreas disease associated with abnormal KSE336, or susceptibility to said disease, comprising: 
 assessing the expression of KSE336 of  claim 1  in a tissue sample comprising pancreas cells, brain cells, or cells derived from pancreas or brain.    
     
     
         11 . A method of  claim 10 , wherein assessing is: 
 measuring expression levels of said gene, determining the genomic structure of said gene, determining the mRNA structure of transcripts from said gene, or measuring the expression levels of polypeptide coded for by said gene.    
     
     
         12 . A method of  claim 1  1, further comprising: 
 comparing said expression to the expression of said gene of a known normal tissue.  
 
     
     
         13 . A method of  claim 10 , wherein said assessing is performed by: 
 Northern blot analysis, polymerase chain reaction (PCR), reverse transcriptase PCR, RACE PCR, or in situ hybridization, and    using a polynucleotide probe having a sequence selected from SEQ ID NO 1 or a complement thereto.    
     
     
         14 . A method of  claim 10 , wherein said disease is astrocytoma, meningioma, pancreatic adenocarcinoma, insulin-dependent diabetes mellitus, Beckwith-Wiedemann syndrome, or congenital hyperinsulinism  
     
     
         15 . A method of assessing a therapeutic or preventative intervention in a subject having a brain or pancreas disease, comprising, 
 determining the expression levels of KSE336 of  claim 1  in a tissue sample comprising brain and pancreas cells, or cells derived from brain and pancreas.    
     
     
         16 . A method for identifying an agent that modulates the expression of KSE336 in brain or pancreas cells, cells derived from brain and pancreas, or brain and pancreas progenitor cells, comprising, 
 contacting a cell population with a test agent under conditions effective for said test agent to modulate the expression of KSE336 of  claim 1  in brain cells, pancreas cells, cells derived from brain or pancreas cells, or brain or pancreas progenitor cells, and    determining whether said test agent modulates said KSE336.    
     
     
         17 . A method of  claim 16 , wherein said agent is an antisense polynucleotide to a target polynucleotide sequence selected from SEQ ID NO 1 which is effective to inhibit translation of said KSE336.  
     
     
         18 . A method of detecting polymorphisms in KSE336 comprising: 
 comparing the structure of: genomic DNA comprising all or part of KSE336, mRNA comprising all or part of KSE336, cDNA comprising all or part of KSE336, or a polypeptide comprising all or part of KSE336, with the structure of KSE336 of  claim 2 .    
     
     
         19 . A method of  claim 18 , wherein said polymorphism is a nucleotide deletion, substitution, inversion, or transposition.  
     
     
         20 . A method of advertising KSE336 for sale, commercial use, or licensing, comprising, 
 displaying in a computer-readable medium a polynucleotide of  claim 1 , effective specific fragments thereof, or complements thereto.    
     
     
         21 . An antibody which is specific-for an amino acid sequence selected from SEQ ID NO 2, 4, or 6.